MX2024000903A - Formas cristalinas. - Google Patents
Formas cristalinas.Info
- Publication number
- MX2024000903A MX2024000903A MX2024000903A MX2024000903A MX2024000903A MX 2024000903 A MX2024000903 A MX 2024000903A MX 2024000903 A MX2024000903 A MX 2024000903A MX 2024000903 A MX2024000903 A MX 2024000903A MX 2024000903 A MX2024000903 A MX 2024000903A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- compositions
- oxoindolin
- phenylbutan
- piperidin
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- -1 (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl) -1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride Chemical compound 0.000 abstract 1
- 102000057413 Motilin receptors Human genes 0.000 abstract 1
- 108700040483 Motilin receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000003840 hydrochlorides Chemical class 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227692P | 2021-07-30 | 2021-07-30 | |
| PCT/JP2022/029430 WO2023008585A1 (en) | 2021-07-30 | 2022-08-01 | Crystalline forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000903A true MX2024000903A (es) | 2024-02-06 |
Family
ID=85087024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000903A MX2024000903A (es) | 2021-07-30 | 2022-08-01 | Formas cristalinas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12552776B2 (enExample) |
| EP (1) | EP4377309B1 (enExample) |
| JP (1) | JP7765130B2 (enExample) |
| KR (1) | KR20240042400A (enExample) |
| CN (1) | CN117616022A (enExample) |
| BR (1) | BR112023025271A2 (enExample) |
| CA (1) | CA3223173A1 (enExample) |
| ES (1) | ES3072067T3 (enExample) |
| MX (1) | MX2024000903A (enExample) |
| TW (1) | TW202321216A (enExample) |
| WO (1) | WO2023008585A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
| US12667578B2 (en) | 2024-07-25 | 2026-06-30 | Visionary Assets, Llc | Cryogenic process for making cannabinoid nanoparticles and compositions made thereby |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006221699A1 (en) | 2005-03-11 | 2006-09-14 | Pfizer Inc. | Crystal forms of an imidazole derivative |
| JP5663743B2 (ja) | 2009-02-27 | 2015-02-04 | ラクオリア創薬株式会社 | モチリン受容体作動活性を有するオキシインドール誘導体 |
| CN103702995B (zh) | 2011-05-18 | 2016-04-13 | 拉夸里亚创药株式会社 | 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式 |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| WO2013164790A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| JP6572414B2 (ja) | 2014-05-20 | 2019-09-11 | ラクオリア創薬株式会社 | ベンズイソオキサゾール誘導体塩 |
-
2022
- 2022-08-01 CA CA3223173A patent/CA3223173A1/en active Pending
- 2022-08-01 MX MX2024000903A patent/MX2024000903A/es unknown
- 2022-08-01 WO PCT/JP2022/029430 patent/WO2023008585A1/en not_active Ceased
- 2022-08-01 EP EP22849645.1A patent/EP4377309B1/en active Active
- 2022-08-01 JP JP2024503927A patent/JP7765130B2/ja active Active
- 2022-08-01 ES ES22849645T patent/ES3072067T3/es active Active
- 2022-08-01 US US18/291,712 patent/US12552776B2/en active Active
- 2022-08-01 CN CN202280048877.0A patent/CN117616022A/zh active Pending
- 2022-08-01 TW TW111128732A patent/TW202321216A/zh unknown
- 2022-08-01 BR BR112023025271A patent/BR112023025271A2/pt unknown
- 2022-08-01 KR KR1020247000169A patent/KR20240042400A/ko active Pending
-
2026
- 2026-01-14 US US19/448,506 patent/US20260146036A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117616022A (zh) | 2024-02-27 |
| BR112023025271A2 (pt) | 2024-02-27 |
| JP2024526952A (ja) | 2024-07-19 |
| EP4377309A4 (en) | 2025-06-25 |
| US20260146036A1 (en) | 2026-05-28 |
| EP4377309C0 (en) | 2026-05-20 |
| TW202321216A (zh) | 2023-06-01 |
| CA3223173A1 (en) | 2023-02-02 |
| US12552776B2 (en) | 2026-02-17 |
| US20240351998A1 (en) | 2024-10-24 |
| ES3072067T3 (en) | 2026-06-29 |
| EP4377309B1 (en) | 2026-05-20 |
| WO2023008585A1 (en) | 2023-02-02 |
| KR20240042400A (ko) | 2024-04-02 |
| JP7765130B2 (ja) | 2025-11-06 |
| EP4377309A1 (en) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| DE60224404D1 (de) | Substiuierte piperidine als melanocortinrezeptor-modulatoren | |
| DE69623899T2 (de) | Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen | |
| DK1871368T3 (da) | Dihydropyridinforbindelser til neurodegenerative sygdomme og demens | |
| CR20220105A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| MX2023002907A (es) | Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300. | |
| TW200820969A (en) | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism | |
| MX2025001312A (es) | Formas cristalinas y sales de un agonista del receptor muscarinico | |
| MX2023007140A (es) | Compuestos farmaceuticos. | |
| NO20076424L (no) | N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser | |
| EA036542B9 (ru) | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора | |
| NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister | |
| CN102753540A (zh) | α4β2神经元烟碱型乙酰胆碱受体的配体 | |
| MX2024011914A (es) | Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida | |
| KR20140051200A (ko) | 4｛3〔시스-헥사하이드로시클로펜타〔ｃ〕피롤2（1ｈ）일〕프로폭시｝벤즈아미드와 아세틸콜린에스테라제 억제제의 회합체 및 이를 함유하는 약제 조성물 | |
| MXPA05004507A (es) | 4-amino-1-(piridilmetil)piperidina sustituida como antagonista del receptor muscarinico. | |
| MX2023012521A (es) | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. | |
| MX2023014547A (es) | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). | |
| NO20090190L (no) | Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate | |
| BR112023025271A2 (pt) | Forma cristalina a e b de sal hcl, composição farmacêutica, formas cristalinas de sal hcl e uso destas, método de tratamento de doenças ou condições mediadas pela atividade do receptor de motilina, processo para preparação da forma cristalina a | |
| NO327074B1 (no) | Cyklisk aminforbindelse, slike forbindelser for bruk som medikament, farmasoytiske blandinger inneholdende slike samt anvendelse av disse for fremstilling av medisin for behandling av sykdommer. | |
| MY210588A (en) | Luminally-acting n-(piperidin-4-yl)benzamide derivatives | |
| PL1853232T3 (pl) | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania | |
| NO20091830L (no) | Spiro-piperidinderivater som VIa reseptorantagonister | |
| ATE229952T1 (de) | Substituierte n-methyl-n-(4-(piperidin-1-yl)-2- arylbutyl)-benzamide zur behandlung von allergischen erkrankungen |